» Articles » PMID: 39859429

Fecal Microbiota Strongly Correlates with Tissue Microbiota Composition in Colorectal Cancer but Not in Non-Small Cell Lung Cancer

Abstract

Microbiota could be of interest in the diagnosis of colorectal and non-small cell lung cancer (CRC and NSCLC). However, how the microbial components of tissues and feces reflect each other remains unknown. In this work, our main objective is to discover the degree of correlation between the composition of the tissue microbiota and that of the feces of patients affected by CRC and NSCLC. Specifically, we investigated tumor and non-tumor tissues from 38 recruited patients with CRC and 19 with NSCLC. DNA from samples was submitted for 16S rDNA metagenomic sequencing, followed by data analysis through the QIIME2 pipeline and further statistical processing with STATA IC16. Tumor and non-tumor tissue selected genera were highly correlated in both CRC and NSCLC (100% and 81.25%). Following this, we established tissue-feces correlations, using selected genera from a LEfSe analysis previously published. In CRC, we found a strong correlation between the taxa detected in feces and those from colorectal tissues. However, our data do not demonstrate this correlation in NSCLC. In conclusion, our findings strongly reinforce the utility of fecal microbiota as a non-invasive biomarker for CRC diagnosis, while highlighting critical distinctions for NSCLC. Furthermore, our data demonstrate that the microbiota components of tumor and non-tumor tissues are similar, with only minor differences being detected.

References
1.
Wynendaele E, Debunne N, Janssens Y, De Spiegeleer A, Verbeke F, Tack L . The quorum sensing peptide EntF* promotes colorectal cancer metastasis in mice: a new factor in the host-microbiome interaction. BMC Biol. 2022; 20(1):151. PMC: 9238271. DOI: 10.1186/s12915-022-01317-z. View

2.
Yang K, Wang S, Ding Z, Zhang K, Zhu W, Wang H . Unveiling microbial dynamics in lung adenocarcinoma and adjacent nontumor tissues: insights from nicotine exposure and diverse clinical stages via nanopore sequencing technology. Front Cell Infect Microbiol. 2024; 14:1397989. PMC: 11385298. DOI: 10.3389/fcimb.2024.1397989. View

3.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

4.
Chen J, Yu X, Wu X, Chai K, Wang S . Causal relationships between gut microbiota, immune cell, and Non-small cell lung cancer: a two-step, two-sample Mendelian randomization study. J Cancer. 2024; 15(7):1890-1897. PMC: 10905411. DOI: 10.7150/jca.92699. View

5.
Tesolato S, Vicente-Valor J, Paz-Cabezas M, Gomez-Garre D, Sanchez-Gonzalez S, Ortega-Hernandez A . Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung Cancers. Biomedicines. 2024; 12(3). PMC: 10967942. DOI: 10.3390/biomedicines12030703. View